← All peptides

Cerebrolysin

Research Use Only
blendSubcutaneous injection

A brain-repair peptide blend derived from pig brain tissue that contains natural nerve-growth factors. It's used clinically to help recover from strokes, traumatic brain injuries, and degenerative brain conditions. Backed by a strong body of research.

What to Expect

1

Week 1–2

Improved mental clarity and focus. Enhanced verbal fluency. Subtle mood elevation. Neurotrophic effects beginning at cellular level.

2

Week 3–6

Significant cognitive enhancement — memory, learning speed, and mental stamina. Improved neuroplasticity. Better stress resilience.

3

Week 8+

Sustained neuroprotective benefits. Long-term cognitive gains, especially in age-related decline. Cumulative neurotrophic effects support ongoing brain health.

Common Side Effects

Injection site reactionsHeadacheDizzinessAgitation (rare)Mild nauseaInsomnia if dosed late in day
Tolerance: None — neurotrophic effects are cumulative
Cycling: 10-20 day intensive cycles (IM or IV daily), 2-4 times per year. Rest 2-3 months between cycles.

Scientific Overview

Cerebrolysin is a porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides (<10 kDa) and free amino acids. Its neurotrophic activity mimics BDNF, GDNF, and CNTF signaling. Clinical trials in acute ischemic stroke (CASTA, n=1,070) demonstrated improved neurological outcomes when administered within 72 hours. The peptide mixture promotes neuronal survival, synaptic plasticity, and neurogenesis through activation of PI3K/Akt and MAPK/ERK pathways. It has been approved in over 50 countries for stroke and traumatic brain injury.

Dosing

5-10 mL injected into muscle daily for 10-20 days. Specific protocols vary depending on the condition being treated.

Practical Guide

Reconstitution

Pre-filled ampoules (1mL, 5mL, 10mL) — no reconstitution needed.

Storage

Store at room temperature. Protect from light. Do not freeze. Check ampoule clarity before use.

Injection Sites

Intramuscular (gluteal, deltoid)IV infusion (diluted in saline)

IM injection for doses up to 5mL. IV infusion for doses >5mL — dilute in 100mL normal saline over 15-30 minutes. Do NOT inject IV push.

Timing

Morning dosing preferred to avoid insomnia. Daily injections during 10-20 day intensive cycles.

Food

No food interactions.

Benefit Profile

🧠 Brain & Cognition
9/10
🩹 Injury Healing
6/10
😌 Mood & Anxiety
4/10
Longevity
3/10

Medical Considerations

Medical oversight requiredNot safe during pregnancy

Contraindications

  • Epilepsy or seizure disorders
  • Severe renal failure
  • Pregnancy/nursing
  • Allergic diathesis

Drug Interactions

MAO inhibitors (avoid concurrent use)Antidepressants (may potentiate effects)Lithium (potential neurotoxicity)

Recommended Monitoring

  • Renal function if pre-existing kidney disease
  • EEG if seizure history
  • Cognitive assessment scores for efficacy

This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.

Pricing

VendorVariantPrice
Limitless Biotech5mL$59.99BEST
Code: PSTACK10Buy

Published Research

20 studies indexed(2013–2025)12 meta-analysises1 clinical trial7 reviews

[Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation].

Kalinin MN, Khasanova DR·Zh Nevrol Psikhiatr Im S S Korsakova·2024
Meta-Analysis

Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series.

Vester JC, Buzoianu AD, et al.·Neurol Sci·2021
Meta-Analysis

Cerebrolysin for acute ischaemic stroke.

Ziganshina LE, Abakumova T, Hoyle CH·Cochrane Database Syst Rev·2020
Meta-Analysis

Cerebrolysin for vascular dementia.

Cui S, Chen N, et al.·Cochrane Database Syst Rev·2019
Meta-Analysis

Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials.

Bornstein NM, Guekht A, et al.·Neurol Sci·2018
Meta-Analysis

Cerebrolysin for acute ischaemic stroke.

Ziganshina LE, Abakumova T, Vernay L·Cochrane Database Syst Rev·2017
Meta-Analysis

Cerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials.

Wang Z, Shi L, et al.·Drug Des Devel Ther·2017
Meta-Analysis

Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials.

Guekht A, Vester J, et al.·Neurol Sci·2017
Meta-Analysis

Cerebrolysin for acute ischaemic stroke.

Ziganshina LE, Abakumova T, Vernay L·Cochrane Database Syst Rev·2016
Meta-Analysis

Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.

Gauthier S, Proaño JV, et al.·Dement Geriatr Cogn Disord·2015
Meta-Analysis
Showing 10 of 20 studies. Search PubMed for the complete list.